Timothy grass extract immunotherapy - Stallergenes Greer plc
Latest Information Update: 16 Jul 2016
At a glance
- Originator Greer Laboratories
- Developer Stallergenes Greer plc
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Seasonal allergic rhinitis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Seasonal-allergic-rhinitis in USA (Sublingual, Drops)
- 04 Dec 2007 Greer initiates enrolment in a phase I trial for allergic rhinitis in high risk patients in USA